Research and Clinical Trials

ADVL1121 Sorafenib in Young Patients With Relapsed/Refractory Solid Tumors
Brief Description  
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, Hepatocellular Carcinoma (HCC, a type of liver cancer), or Papillary Thyroid Carcinoma (PTC, a type of thyroid cancer). Sorafenib is taken by mouth two times each day in repeating 28 day cycles. Patiens may participate in the study for up to two years in the absence of disease progression or serious side effects.
Who may be Eligible  

  1. Patients with relapsed or refractory Rhabdomyosarcoma (RMS), Wilms Tumor, Hepatocellular Carcinoma (HCC), or Papillary Thyroid Carcinoma (PTC). Patients must have radiographically measurable disease.
  2. Patients must have recovered from the adverse effects of all previous cancer treatments.
  3. Patients with adequate bone marrow, liver, kidney, lung, and pancreatic function.
  4. Patients with age and gender appropriate blood pressure (and NOT on any medicines to control blood pressure)
IRB Number  
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Julie  A, Chasnis
Phone:  (704) 446-5154  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204